We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Technologies Fuel EU Diagnostics Market

By HospiMedica staff writers
Posted on 04 Oct 2005
Sparked by new technologies and other medical advances, the European in vitro diagnostics (IVD) market is expected to reach U.S.$43 billion in 2011, up from $28.7 billion in 2004, according to a new report from Frost & Sullivan (Palo Alto, CA, USA), an international consulting firm.

The expanding aged population and molecular diagnostics will also help boost the IVD market, although cost containment and changing economic conditions worldwide are hindering the uptake of IVD technologies. More...
This is particularly true in developing nations in Asia, Latin America, and Africa, where poor healthcare infrastructures and struggling economies impede modernization and create environments that are extremely price sensitive. Distribution, local suppliers, and minimal expenditures for healthcare also create hurdles to market growth.

Recently, healthcare awareness programs and government initiatives to increase spending have stimulated improvements in European countries, creating opportunities for future growth. As markets become more competitive and consumers raise demands, low prices, multiple tests on a single platform, and customer service gain importance. Understanding specific markets and clinical needs is increasingly important to promote adoption of new technologies, according to Silvia Cerqueira, an analyst with Frost & Sullivan. "New IVD systems must also address unmet needs and provide substantial added value.” Smaller companies can combat regulatory challenges by collaborating with larger companies and benefiting from their experience and economic resources.

Discoveries and innovations in molecular diagnostics are propelling the advancement of personalized medicine and creating new growth opportunities for IVDs. As manufacturers concentrate on providing greater benefits such as early diagnosis, improved decision-making, and better monitoring of treatment, the market will maintain its strong growth trajectory. Rising insurance coverage in such countries as France, Spain, and Germany will also contribute to positive trends in the market.




Related Links:
Frost & Sullivan

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.